Business Wire
Merck Hosts 2019 Investor Day Outlining Business Momentum, Strong Expected Growth and Focus on Innovative Research and Development
At a meeting with the investment community today, Merck (NYSE: MRK), known as MSD outside the United States and Canada, will outline how its science-led
Dana-Farber Announces $20 Million Gift from the Saverin Family for Metastatic Breast Cancer Research
A $20 million gift announced today from the Saverin Family will establish the Saverin Breast Cancer Research Fund at Dana-Farber Cancer Institute under the direction
Cancer Prevention Pharmaceuticals (CPP) Reports FAP Phase 3 Clinical Trial Results at Digestive Disease Week Conference
Cancer Prevention Pharmaceuticals, Inc. (CPP) recently reported results from its pivotal Phase 3 trial of CPP-1X/sul for adults with familial adenomatous polyposis (FAP) at the
Spectrum Pharmaceuticals Appoints Elizabeth Czerepak to its Board of Directors
Spectrum Pharmaceuticals, Inc. (NASDAQ-GS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today the appointment of Elizabeth Czerepak to the Board
Clinipace’s Data Aggregation Solution Will Be Showcased at DIA Annual Meeting
Clinipace, a global full-service contract research organization (CRO), will showcase Clarity Stack® clinical technology at the 2019 Drug Information Association (DIA) Annual Meeting. Clarity Stack
Globally Recognized Nephrologist Joins Dicerna™ to Support Continued Development of DCR-PHXC for the Treatment of Primary Hyperoxaluria
Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced the appointment of Prof.
Elligo Health Research Strengthens Ability to Grow and Enable Physician Practice Clinical Research
Elligo Health Research, a healthcare-enabling research organization, welcomes Brandon Cormier, Jody Casey, and Faith Holmes, MD, FAAFP, AAHPM, HMDC, to its team. The new team
Axial Biotherapeutics Announces $10M Investment from Taiho Ventures to Access Axial’s Expertise in the Gut-Brain Axis
Axial Biotherapeutics, a biotechnology company dedicated to building a unique class of gut-targeted therapeutics for neurodegenerative diseases and neurodevelopmental disorders, today announced a direct investment
Pear Therapeutics to Participate in the Oppenheimer Summit for Emerging Biotechnology
Pear Therapeutics, Inc., the leader in prescription digital therapeutics (PDTs), today announced that Christopher D.T. Guiffre, J.D., M.B.A., Chief Financial Officer and Chief Operating Officer,